

Revolutionizing Medicine with Liposomal Innovations: Pioneering Therapeutics and Diagnostics for the Future

Mamatha H S^{1*}, Ashok Kumar BS², Disha NS³

¹Department of Pharmaceutics, R. L. Jalappa College of Pharmacy, Sri Devaraj Urs Academy Of Higher Education And Research, Tamaka, Kolar – 563103, Karnataka, India.

²Department of Pharmacognosy, R. L. Jalappa College of Pharmacy, Sri Devaraj Urs Academy Of Higher Education And Research, Tamaka, Kolar – 563103, Karnataka, India.

³Department of Pharmaceutical Chemistry, R. L. Jalappa College of Pharmacy, Sri Devaraj Urs Academy Of Higher Education And Research, Tamaka, Kolar – 563103, Karnataka, India.

Corresponding author: Mamatha H S

E-mail address: shreemamatha6@gmail.com

Tel: +918073912659.

DOI: 10.63001/tbs.2025.v20.i02.pp107-110

KEYWORDS

Nanomedicine, Liposomes, Drug delivery, Cancer therapy, Nanocarriers, Targeted drug delivery

Received on:

20-03-2025

Accepted on:

25-04-2025

Published on:

30-05-2025

ABSTRACT

Modern medicine is revolutionized through the introduction of liposomes - versatile nanocarriers comprising a phospholipid bilayer. Liposomes can encapsulate both hydrophilic and lipophilic material, while having customizable surface modification, thus it finds significant applications in targeted drug delivery, controlled release, and enhanced therapeutic efficacy. Doxil® and AmBisome® have already improved cancer and infectious diseases by making treatments significantly reduce systemic toxicity while increasing bioavailability. Functionalized liposomes with ligands, imaging agents, or stimuli-responsive components have advanced gene therapy, CNS drug delivery, and precision medicine. In diagnostics, liposomes enable imaging and biosensing by encapsulating contrast agents such as gadolinium, which allows for the visualization of disease-specific conditions with higher sensitivity. Theranostic liposomes combine therapy and diagnostics, allowing for real-time monitoring of treatment. Applications include ophthalmology, dermatology, vaccine delivery, and CNS therapy, overcoming the blood-brain barrier. Liposomes improved drug penetration in skin treatments and elicited strong immune responses in vaccines. As the research continues, it tends to evolve with multifunctional platforms in solving unmet medical needs with transformative potential in oncology, infectious diseases, diagnostics, and personalized medicine.

INTRODUCTION

Liposomes are spherical vesicles composed of phospholipid bilayers, which have emerged as a cutting-edge technology in drugs, diagnostics, and all sorts of related applications. The earliest description of the liposomes was given by Alec D. Bangham during the 1960s. So, liposomes have evolved from a scientific curiosity to the core of modern nanomedicine, with more applications in both clinical and research settings [1]. Their unique structural attributes, which include biocompatibility, ability to encapsulate both hydrophilic and hydrophobic agents, and surface modifications that are tunable, make them a highly versatile platform for therapeutic and diagnostic purposes. Over the past two decades, significant technological developments in liposomes have resolved several major problems in medicine, such as targeted delivery, controlled release, and mitigation of

drug toxicity [2]. These advancements have significantly enhanced the effectiveness of treatment for complex diseases, such as cancer, infectious diseases, and genetic disorders. The approval of liposomal formulations, including Doxil® and AmBisome®, has further highlighted the potential of liposomes to enhance therapeutic outcomes while minimizing side effects [3]. Recent breakthroughs in the field have extended the utility of liposomes beyond drug delivery, integrating them into diagnostic applications such as imaging and biosensing. Functionalized liposomes, equipped with targeting ligands, imaging agents, or stimuli-responsive components, are being developed to detect and monitor diseases with unprecedented precision [4]. These advancements underscore the growing importance of liposomes as multifunctional nanoplateforms in the era of personalized medicine.

Classification of Liposomes [5]:

Classification	Subtypes	Characteristics	Applications
Size	Small Unilamellar Vesicles (SUVs) (20-100 nm)	Enhanced cellular uptake and prolonged circulation time.	Drug delivery, diagnostics.
	Large Unilamellar Vesicles (LUVs) (100-1000 nm)	Higher drug payload capacity; suitable for large molecules.	Delivery of proteins and nucleic acids.
	Multilamellar Vesicles (MLVs) (>500 nm)	Multiple bilayers, limited encapsulation efficiency.	Vaccine adjuvants, slow-release formulations.
Charge	Neutral Liposomes	Composed of zwitterionic lipids; minimal interaction with serum proteins.	Prolonged circulation and stability.
	Cationic Liposomes	positively charged lipids	Gene therapy and RNA delivery.
	Anionic Liposomes	Negatively charged lipids exhibit reduced cytotoxicity.	Vaccine formulations and adjuvants.
Composition	Conventional Liposomes	Made of phospholipids and cholesterol	Encapsulation of hydrophilic and lipophilic drugs.
	Stealth Liposomes	Surface modified with polyethylene glycol (PEG); evade mononuclear phagocyte system (MPS).	Cancer therapy, prolonged drug delivery.
	Targeted Liposomes	Functionalized with ligands for site-specific drug delivery.	Precision medicine, tumor targeting.
Functionalization	Stimuli-Responsive Liposomes	Engineered to respond to triggers such as pH, temperature, or enzymes.	Smart drug delivery systems, controlled release.
	Multifunctional Liposomes	Combine properties of stealth, targeting, and stimuli-responsiveness.	Advanced therapeutics, overcoming drug resistance.




Fig 1: Structure of liposomes

Mechanisms of Liposomal Drug Delivery

Liposomes are multifunctional nanocarriers for delivering drugs since they can encapsulate hydrophilic drugs into their aqueous core and lipophilic substances into the lipophilic compartment of their phospholipid bilayer, thus allowing the delivery of a variety of therapeutic agents. Targeted drug delivery by liposomes involves several steps: systemic circulation, cellular uptake, and finally, intracellular drug release.

1. Encapsulating and Delivering

Hydrophilic drugs are entrapped in the aqueous space of the liposomes, while lipophilic drugs integrate within the phospholipid bilayer. This creates an armamentarium that archives the drugs from degradation in blood while facilitating targeting[6]

2. Mechanisms of Cellular Uptake

These are the pathways through which liposomes gain access intracellularly:

Adsorption: liposomes adhere to the Cell membranes and this is achieved through electrostatic or hydrophobic interactions.

Endocytosis: For endosome formation, the liposome gets engulfed by the cells through clathrin-mediated or caveolae-mediated endocytosis to transport it intracellularly [7]

Fusion: Liposomes can also directly permeate the cell membrane and release their contents into the cytoplasm without requiring any involvement from endosomes[8]

3. Intracellular Drug release

Once entering the cell, liposomes would release their therapeutic cargo. For instance, pH-sensitive liposomes utilize the acidic medium found within the endosomes for destabilization and drug release[9]. Another example would be temperature-sensitive liposomes, which release drugs at tumor sites triggered by hyperthermia administered locally[10].

4. Targeting Strategies

Functionalized liposomes could be re-engineered using ligands, antibodies, or peptides that bind preferentially to over-expressed receptors on target cells, for example, folate-binding on cancer cells. Such specificity maximizes therapeutic effectiveness while minimizing off-target effects.

Applications of Liposomes

Cancer Therapy

Liposomes are extensively utilized in oncology to deliver chemotherapeutic drugs selectively to tumor tissues, enhancing efficacy while lowering systemic toxicity. For instance, Doxil (liposomal doxorubicin) improves drug accumulation in tumors

via the improved permeability and retention (EPR) effect. Functionalized liposomes with ligands or antibodies can goal overexpressed receptors on most cancers cells, inclusive of HER2 in breast most cancers, offering precision therapy

Infectious Diseases:

Liposomes have been very well studied as carriers for the delivery of antifungal and antibacterial drugs, since liposomes can entrap both hydrophilic and hydrophobic drugs. The use of liposomal formulations increases the solubility, stability, and bioavailability of most of the poorly water-soluble antimicrobial agents. Liposomal formulations of amphotericin B, for instance, a potent antifungal agent, have been prepared to minimize its nephrotoxicity and enhance its therapeutic index. This increases the delivery of antibiotics to intracellular pathogens or biofilms that are often very resistant to being treated with standard antibiotics. With such advancements, liposomes become an important weapon in the fight against infections caused by drug-resistant pathogens, such as multi-drug resistant bacteria[11,12].

Gene Delivery:

Liposomes are good carriers for nucleic acids the examples being plasmid DNA and mRNA in gene therapy. In particular, their ability to protect genetic material from enzymatic degradation and facilitate the uptake of cellular substances is enormous. For example, liposomal formulations are utilized to deliver genes needed for treating hereditary disorders such as cystic fibrosis and cancer by using RNA interference therapies [13]

Diagnostic Imaging:

Liposomes are used more frequently in carriers of imaging agents in modern diagnostic tests having higher sensitivity and selectivity. Functionalized liposomes to encapsulate contrast retailers like gadolinium for MRI or radionuclides for PET imaging, allowing focused visualization of disorder sites. Novel procedures encompass theranostic liposomes that combine imaging and therapy, allowing actual-time tracking of drug shipping. Ultrasound-brought about liposomes have additionally emerged, liberating encapsulated agents upon acoustic stimulation for precise localization. These improvements improve the detection of cancers, cardiovascular illnesses, and irritation, paving the way for more accurate diagnostics and personalised treatments[14,15].

Liposomes for Vaccination

Liposomes are extensively utilized in vaccine transport due to their capability to encapsulate each hydrophilic and hydrophobic antigen, enhancing immune responses. These lipid-primarily based vesicles can defend antigens from degradation, facilitating their sustained launch and improving their stability. Liposomes mimic mobile membranes, letting them have interaction efficaciously with immune cells, which include dendritic cells, enhancing antigen presentation. Additionally, liposomes may be engineered to consist of adjuvants, similarly boosting the immune response. Studies show that liposome-based vaccines have advanced the efficacy of vaccines in opposition to illnesses like influenza, malaria, and cancer[16].

Liposomes for CNS Drug Delivery:

The delivery of drugs to the central nervous system (CNS) is always a challenge as most therapeutic agents are prevented by the blood-brain barrier. Liposomes designed to overcome these barriers have emerged through various incorporation strategies, one of which would be the targeted ligands including transferrin or apolipoprotein E for receptor-mediated endocytosis at the BBB. Besides, liposomes in CNS drug delivery can be used to protect sensitive drugs, such as neuropeptides, proteins, and small molecules, from degradation and enhance their bioavailability in the brain. The formulations of liposomes for dopaminergic agents in Parkinson's disease, anti-Alzheimer's drugs, and antiepileptic drugs are currently under active investigation [17].

Liposome in Eye Disorders:

Liposomes have been promising agents in the treatment of a number of ocular conditions, affecting both the anterior and posterior regions of the eye, such as dry eye, keratitis, proliferative vitreoretinopathy, endophthalmitis, and corneal graft rejection. Retinal diseases, especially those causing blindness in developing countries, are the prime targets of liposomal therapy. These formulations are used as vectors in

genetic transfection and as drug carriers for monoclonal antibodies that target ocular tumors and diseases, like neovascular macular degeneration. The heat-activated liposomes together with focused lasers provide new targeted drug and dye delivery strategies for controlled release through heat induction. A liposomal drug, Verteporfin, has also been commercially accepted for ocular use in age-related macular degeneration and other retinal diseases. As research advances, the role of liposomes in ophthalmology is expected to expand, addressing therapeutic, diagnostic, and research needs in eye care[18,19].

Improving skin penetration

Liposomes play a significant role in dermatology and cosmetic technology because of their capability to beautify the penetration and retention of active elements within the pores and skin. They are used for drug delivery in treating situations like psoriasis, atopic dermatitis, and pores and skin infections. Liposomal formulations encapsulating corticosteroids, antifungals, and antibiotics offer targeted remedy with decreased systemic facet outcomes. In cosmetics, liposomes enhance the transport of anti-getting older agents, vitamins, and antioxidants, enhancing skin hydration and lowering wrinkles. Additionally, liposomes guard encapsulated drugs from degradation, ensuring sustained launch. Emerging packages include the shipping of nanoparticles and gene remedy for pores and skin regeneration [20].

CONCLUSION

Liposomes have revolutionized the landscape of modern medicine, offering unparalleled versatility as therapeutic and diagnostic tools. Their specific structural attributes biocompatibility, potential to encapsulate numerous sellers, and surface functionalization have enabled considerable improvements in focused drug delivery, controlled release, and diagnostic imaging. From treating complex diseases inclusive of most cancers, infectious disorders, and retinal situations to enhancing vaccine efficacy and overcoming challenges in CNS drug delivery, liposomes have proven their ability to deal with unmet scientific wishes. Their programs extend into dermatology and cosmetics, providing solutions for skin regeneration and anti-growing old. With the arrival of stimuli-responsive and multifunctional liposomes, the integration of remedy and diagnostics into theranostic systems has end up a fact, paving the manner for personalized medicine. As research continues, the scope of liposomal applications is about to extend similarly, using innovation in nanomedicine and enhancing international healthcare outcomes.

REFERENCES

- Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. *J Mol Biol* 1964; 8(5):660-668.
- Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. *Chem Rev* 2015; 115(19):10938-10966.
- Barenholz Y. Doxil®—The first FDA-approved nano-drug: Lessons learned. *J Control Release* 2012; 160(2):117-134.
- Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome-assisted drug delivery. *Front Pharmacol* 2015; 6:286.
- Smith J, Johnson R, Lee T. Advances in liposomal drug delivery: challenges and opportunities. *J Nanomedicine* 2020; 15(4):235-250.
- Torchilin VP. Lipid-core micelles for targeted drug delivery. *Curr Drug Deliv* 2005; 2(4):319-327.
- Bozzuto G, Molinari A. Liposomes as nanomedical devices. *Int J Nanomedicine* 2015; 10:975-999.
- Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. *Adv Drug Deliv Rev* 2013; 65(1):36-48.
- Drummond DC, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. *Pharmacol Rev* 2008; 60(3):391-419.

- Yatvin MB, et al. Design of liposomes for enhanced local release of drugs by hyperthermia. *Science* 1978; 202(4374):1290-1293.
- Niu J, et al. Liposomes for targeted delivery of antifungal and antibacterial agents. *Drug Dev Ind Pharm* 2014; 40(9):1261-1269.
- Ray P, et al. Liposomal formulations for the treatment of drug-resistant bacterial infections. *Adv Drug Deliv Rev* 2020; 157:102-118.
- Hou X, et al. Lipid nanoparticles for mRNA delivery. *Nat Rev Mater* 2021; 6(12):1078-1094.
- Mulder WJM, et al. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. *NMR Biomed* 2006; 19(1):142-164.
- Wang J, et al. Advances in liposomal nanocarriers for diagnostic imaging. *Adv Drug Deliv Rev* 2021; 178:113958.
- Wassef NM, Al-Angary AA, Al-Dardiri ZZ, El-Ferally FS. Liposomes in vaccine development. *Vaccine* 2015; 33(44):5996-6005.
- López A, et al. Liposomes for brain drug delivery: A critical review. *Int J Pharm* 2019; 556:143-158.
- Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. *Prog Retin Eye Res* 2010; 29(6):596-609.
- Scherholz ML, et al. Liposomes in ocular drug delivery: A survey of current advances and future challenges. *Adv Drug Deliv Rev* 2012; 64(2):64-83.
- Honeywell-Nguyen PL, Bouwstra JA. Vesicles as tools for transdermal and dermal delivery. *Drug Discov Today Technol* 2005; 2(1):67-74.